relugolix, estradiol hemihydrate, and norethindrone acetate

CHEBI:CHEBI_746990

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
2556800
product_type
DRUG FOR FURTHER PROCESSING
marketing_category
DRUG FOR FURTHER PROCESSING
listing_expiration_date
20251231
route
ORAL
dosage_form
TABLET, FILM COATED
pharm_class_moa
Gonadotropin Releasing Hormone Receptor Antagonists [MoA]
pharm_class
Gonadotropin Releasing Hormone Receptor Antagonists [MoA]
active_ingredient_strength
1 mg/1
nui
N0000187064
package_marketing_start_date
01-JUN-21
marketing_start_date
20210526
generic_name
relugolix, estradiol hemihydrate, and norethindrone acetate
brand_name
Myfembree
brand_name_base
Myfembree
product_ndc
63285-891
application_number
NDA214846
labeler_name
Patheon, Inc.
manufacturer_name
Sumitomo Pharma America, Inc
spl_id
8dc00205-9523-44a5-8fbc-24c0c44ebf77
active_ingredient_name
RELUGOLIX
package_ndc
63285-891-00
package_description
51975 TABLET, FILM COATED in 1 DRUM (63285-891-00)
unii
P76B05O5V6
spl_set_id
fc3feb73-cc84-43a8-aa32-b262460495e8
upc
0372974415013
pharm_class_epc
Gonadotropin Releasing Hormone Receptor Antagonist [EPC]
pharm_class_pe
Decreased GnRH Secretion [PE]
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class